Article Details
Retrieved on: 2021-05-21 15:51:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
It is also developing two monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical ...
Article found on: www.investorsobserver.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here